AnaptysBio, Inc. (0HFQ)
LSE
Real-time Data
07:00 AM
Day's Range
53.8452 wk Range
19.82Overview - 0HFQ - AnaptysBio, Inc.
Key Statistics
Valuation
Enterprise Value
1.58B
Price / Book
‪124.80‬
EV / EBITDA
‪38.34‬
Profitability
Profit Margin
‪-11.52%‬
Operating Margin
‪-135.53%‬
Return on Assets
‪6.78%‬
Return on Equity
‪-114.55%‬
Ownership
Shares Outstanding
26.75M
Float
19.79M
Held by Insiders
‪5.67%‬
Held by Institutions
‪106.42%‬
Price stats
Beta
‪0.40‬
50-Day Avg
‪21.59‬
200-Day Avg
‪21.15‬
Market Cap - 0HFQ - AnaptysBio, Inc.
Peers - 0HFQ - AnaptysBio, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on LSE.
- 0HFQLSEAnaptysBio Inc.1.46BMarket Cap+61.43%52-week change—P/E (Trailing)‪-11.52%‬Profit Margin
- 0MGBLSEGenmab A/S168.08BMarket Cap+14.99%52-week change29.66P/E (Trailing)‪29.01%‬Profit Margin
- 0QZULSEVertex Pharmaceuticals Incorporated Common Stock129.81BMarket Cap+24.36%52-week change0.54P/E (Trailing)‪34.99%‬Profit Margin
- 0R2MLSERegeneron Pharmaceuticals, Inc.84.57BMarket Cap+27.23%52-week change0.11P/E (Trailing)‪27.86%‬Profit Margin
- 0A45LSEModerna Inc.70.30BMarket Cap+83.56%52-week change53.96P/E (Trailing)‪11.32%‬Profit Margin
- 0QW0LSEargenx SE50.13BMarket Cap+25.52%52-week change40.43P/E (Trailing)‪-47.51%‬Profit Margin
- 0NZTLSEUCB SA42.62BMarket Cap+1.46%52-week change123.24P/E (Trailing)‪6.45%‬Profit Margin
Profile Summary - 0HFQ - AnaptysBio, Inc.
About
AnaptysBio Inc. is a clinical-stage biotechnology company focused on developing innovative immunology therapeutics for autoimmune and inflammatory diseases. It advances antibody-based drug candidates that modulate immune pathways, including rosnilimab, a PD-1 agonist and pathogenic T cell depleter studied in…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
